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Single-photon emission computed tomographic imaging with tech-
netium-99m teboroxime during exercise has been found to be 
feasible and the results correlate with those obtained with 
thallium-201. This study examined the feasibility of this technique 
and compared tomographic imaging with technetium-99m te-
boroxime during adenosine-induced coronary hyperemia with 
thallium-201 imaging. With the patient positioned on the imaging 
table, adenosine was infused at a rate of 140 #Lg/kg per min for 
6 min. At 4 min, 20 to 25 mCi (740 to 925 MBq) of technetium-
99m teboroxime was injected intravenously and imaging was 
started as soon as the infusion was completed with use of a 180° 
anterior arc and 32 stops at 10 s/stop (total imaging time 7.8 min). 
Rest images were obtained 60 to 90 min later with use of a similar 
dose of technetium-99m teboroxime. Exercise tomographic thal-
lium images were obtained within 2 weeks of the teboroxime 
studies. 
In the 20 patients studied, the teboroxime images were normal 
in 2 (50%) of 4 normal subjects and abnormal in 15 (94%) of 16 
Recently, two technetium-labeled myocardial perfusion im-
aging agents were approved for clinical use: technetium-99m 
sestamibi (hexakis 2-methoxy-2-isobutyl isonitrile) and 
technetium-99m teboroxime. These agents differ from each 
other and from thallium in many aspects involving pharma-
cokinetics and physical characteristics necessitating dif-
ferent imaging protocols (1-6). Unlike thallium, teboroxime 
(Cardiotec, Squibb Diagnostics) is lipophilic, neutrally 
charged and not dependent on an enzymatic mechanism for 
uptake. Furthermore, the dose and energy level of teborox-
ime are much higher than those ofthallium-201. Teboroxime 
has a very short half-life; the effective half-life in humans is 
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patients with coronary artery disease; 4 of the 15 had a fixed defect 
and 11 a reversible defect. There was agreement between teborox-
ime and thallium studies in 16 patients (80% ), in 319 (80%) of 400 
segments and in 50 (83%) of 60 vascular segments (p < 0.05). In 
two normal subjects, an apparent fixed defect involving the 
inferior wall was seen on the teboroxime but not the thallium 
images and was thought to be due to an attenuation artifact 
secondary to extracardiac activity in the left lobe of the liver. 
There were no clinically significant adverse events. 
Thus, this preliminary report shows that teboroxime tomo-
graphic imaging during adenosine infusion is feasible and conve-
nient. This method combines the strengths of both agents: a very 
short half-life (12 min for teboroxime and 10 s for adenosine), a 
rapid imaging sequence (immediately after completion of infu-
sion), maximal coronary hyperemia and a short acquisition pro-
tocol (7 .8 min). This technique should be an acceptable alternative 
to exercise thallium-201 imaging. 
(JAm Coil Cardio/1992;19:307-12) 
approximately 12 min, which mandates a rapid imaging 
protocol (7 ,8). 
We previously showed (6) that single-photon emission 
computed tomographic (SPECT) imaging with a single-head 
gamma camera is feasible with teboroxime exercise testing if 
imaging is started as soon as the exercise is terminated and 
the imaging protocol is modified to considerably decrease 
the acquisition time. We showed that decreasing the imaging 
time from 40 s/stop as used with thallium to 10 s/stop is 
sufficient to produce high quality teboroxime images. This 
procedure effectively reduces the total time for 180° SPECT 
imaging using the "step and shoot" protocol from 24 to 
7.8 min. With continuous acquisition, the imaging time may 
be shorter, but this option is not available in our system. 
We also investigated (9) the results of SPECT thallium 
imaging during coronary hyperemia induced by adenosine, 
an important short-acting coronary vasodilator with a half-
life of <10 s. Our results show that adenosine-thallium 
imaging is a highly accurate method for detecting coronary 
artery disease. Wilson et al. (10) showed that the degree of 
coronary hyperemia induced by intravenous adenosine at 
the currently recommended dose is comparable to that 
0735-1097/92/$5.00 
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Table 1. Clinical Characteristics of the 20 Study Patients 
Age (yr) (mean ± SD) 
Hypertension 
Diabetes mellitus 
ECG Q wave MI 
Nitrates 
Beta-adrenergic blocking agents 
Calcium channel blocking agents 
No.(%) 
60 ± 10 
9 (45) 
2 (10) 
8 (40) 
11 (55) 
11 (55) 
15 (75) 
ECG Q wave MI = electrocardiographic Q wave myocardial infarction. 
achieved by intracoronary papaverine and is roughly four-
fold higher than the rest flow in normal coronary arteries. 
An important and unique characteristic of teboroxime 
is that its extraction remains very high (>90%) even at 
very high flow rates such as those achieved with adenosine 
(7). In this respect the agent is significantly different from 
technetium-99m sestamibi and thallium. 
The purposes of this study, therefore, were to examine the 
feasibility of SPECT teboroxime imaging during adenosine-
induced coronary hyperemia and to compare the results with 
those obtained with exercise SPECT thallium imaging. 
Methods 
Study patients (Table 1). There were 20 patients (17 men 
and 3 women); 4 of these patients had either normal coro-
nary angiograms (n = 2) or <5% pretest probability of 
coronary artery disease (n = 2). The remaining 16 patients 
had coronary artery disease defined either by coronary 
angiography showing ~50% stenosis in one or more major 
coronary arteries (n = 14) or by previous Q wave myocardial 
infarction (n = 2). There were two patients with previous 
coronary artery bypass grafting and recurrent angina due to 
graft occlusion documented on repeat angiography. None of 
the patients had unstable angina, recent myocardial infarc-
tion, active bronchospastic disease, hypersensitivity on a 
previous exposure to adenosine or second degree or greater 
atrioventricular block. The selection was based primarily on 
the willingness of the patients and their referring physicians 
to participate in the study. All patients signed a consent form 
approved by the Institutional Review Board of the medical 
center. 
Study design. At the time of the activation of this proto-
col, both adenosine and teboroxime were investigational 
agents. All xanthine-containing medications and oral dipyr-
idamole were discontinued for ~24 h before the adenosine-
teboroxime testing. Caffeine-containing beverages were 
withheld on the morning of the test. All cardiac medications 
were continued until the day of the stress test. 
Adenosine infusion and imaging. The adenosine infusion 
protocol is similar to that used with thallium-201 (11). In 
brief, two intravenous lines were started, one to infuse the 
adenosine, the second to inject the teboroxime. The patients 
were positioned on the imaging table, adenosine infusion 
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was performed under constant electrocardiographic (ECG) 
monitoring and blood pressure was obtained every minute 
during the infusion and for 5 min after the infusion. Adeno-
sine was infused at a rate of 140 JLglkg per min for 6 min; 
after 4 min, 20 to 25 mCi of technetium-99m teboroxime (740 
to 925 MBq) was injected. As soon as the infusion was 
completed, imaging was started. Single-photon emission 
computed tomographic (SPECT) imaging was performed 
with use of a 180° anterior arc from 45° left posterior oblique 
to 45° right anterior oblique and 32 stops at 6° angles at 
10 s/stop. A standard filtered-back projection technique was 
employed with use of a Butterworth filter with a power of 10 
and a cutoff frequency of 0.3 cycle/cm. From the original 
transaxial tomograms, oblique angled tomograms in the 
short- and long-axis views were obtained at 6 mm/slice. The 
rest images were obtained with a second injection of 20 to 
25 mCi of technetium-99m teboroxime 60 to 90 min after the 
stress study and were processed in a fashion similar to that 
of the stress images. 
Exercise testing. All patients also underwent exercise 
thallium-201 imaging within 2 weeks (mean 7 ± 8 days) of the 
adenosine-teboroxime studies using a standard protocol pre-
viously described from our laboratory (12). Briefly, 3 mCi 
(111 MBq) of thallium-201 was injected at peak exercise, 
tomographic images were obtained within 5 min of termina-
tion of the exercise with use of 32 stops at a 180° anterior arc 
with 40 s/stop. The Ramp-Hanning filter was used for 
reconstruction. Delayed (4 h) images were obtained after 
reinjection of 1 mCi of thallium-201 to obtain the reinjection 
images. The thallium and teboroxime images were inter-
preted by consensus of two readers (A.I. and J.H.) who had 
no knowledge of the clinical data or thallium results. The 
perfusion pattern was assessed in 20 segments in three 
short-axis slices and one vertical long-axis slice at the 
mid-ventricular level. The short-axis slices were chosen at 
the apical, mid and basal levels of the left ventricular cavity; 
each slice was divided into six segments, one anterior, one 
inferior, two septal and two lateral. The apex was inter-
preted from the mid-vertical long axis in two segments 
(anterior and inferior). The perfusion pattern in each seg-
ment was assessed as either normal or abnormal (reversible, 
partially reversible or fixed abnormality). 
Statistical analysis. The results were expressed as mean 
values ± SD when appropriate. Discrete and continuous 
variables were compared by using the chi-square or the 
Student's t test as appropriate. A probability value <0.05 
was considered statistically significant. 
Results 
The hemodynamic and ECG responses to exercise and 
adenosine infusion are shown in Table 2. The peak heart rate 
and systolic blood pressure, as expected, were significantly 
higher during exercise. The side effects of adenosine in this 
small sample size are shown in Table 3. Most side effects 
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Table 2. Hemodynamic and Electrocardiographic Responses to 
Exercise and Adenosine Infusion in 20 Patients 
p 
Exercise Adenosine Value 
Peak heart rate (beats/min) 131 ± 24 84 ± 16 0.0001 
Blood pressure (mm Hg) 
Peak systolic 179 ± 23 123 ± 16 0.0001 
Peak diastolic 87 ± 13 74 ± 11 0.0003 
ST segment depression 4 (20%) 3 (15%) NS 
were transient and none required reversal with aminophyl-
line. 
Results of technetium-99m teboroxime imaging. The te-
boroxime images were normal in two offour patients without 
significant coronary artery disease. In the other two patients, 
an apparent fixed defect was seen in the inferior wall on both 
adenosine and rest images. The teboroxime images were 
abnormal in 15 (94%) of 16 patients with coronary artery 
disease, showing a fixed abnormality in 4 patients and a 
reversible abnormality (with or without an associated fixed 
abnormality) in 11 patients. There were 14 patients with an 
inferior defect; 12 of these patients had a corresponding 
thallium defect. Of the remaining two patients, one had 
isolated left anterior descending artery disease and one had 
residual stenosis after angioplasty of the right coronary 
artery. Figure 1 shows representative images of fixed, par-
tially reversible and reversible defects. 
Liver uptake. In most patients, the liver teboroxime 
uptake did not interfere with the quality of the SPECT 
images. However, as mentioned earlier, in two patients, an 
apparently fixed abnormality was seen involving the inferior 
wall in both the rest and the adenosine images. In these two 
patients, the left lobe of the liver was prominent and very 
close to the inferior surface of the left ventricle. The rest 
studies demonstrated more intense liver teboroxime uptake 
than did the adenosine studies because they were performed 
after the adenosine studies and therefore demonstrated 
residual liver uptake from the latter studies. Intense uptake 
in the left lobe of the liver was not seen in the patients with 
coronary artery disease. Furthermore, most patients with an 
inferior wall abnormality on teboroxime images also had a 
corresponding abnormality on thallium study. Nevertheless, 
Table 3. Side Effects of Adenosine in 20 Patients 
Chest pain 
Dyspnea 
Flushing 
Gastrointestinal discomfort 
ZO or 3° A V block (transient) 
Severe hypotension 
Ventricular arrhythmias 
Headache 
A V = atrioventricular. 
No.(%) 
8 (40) 
9 (45) 
13 (65) 
I (5) 
I (5) 
0 
0 
I (5) 
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attenuation artifacts in the inferior wall should be considered 
in patients with coronary artery disease who also have 
intense uptake in the left lobe of the liver. 
Comparison between adenosine-teboroxime and exercise 
thallium imaging. Thallium images were normal in two 
patients without significant coronary artery disease; in one 
subject with left bundle branch block, a reversible septal 
abnormality was noted. The thallium images were abnormal 
in 14 (88%) of 16 patients with coronary artery disease. Of 
these, 3 had a fixed and 11 a reversible perfusion defect. 
There was agreement between the teboroxime and thallium 
images in 16 patients (80%) (Fig. 2); in 50 (83%) of 60 
vascular territories and in 319 (80%) of 400 segments (Fig. 3) 
(p < 0.05 for each). 
Discussion 
Technetium-99m teboroxime imaging. This technetium-
labeled perfusion imaging agent is a neutral lipophilic com-
plex of a class known as boronic acid adducts of technetium 
dioxime complexes (1-4). It has a higher extraction fraction 
than thallium but a shorter retention time. Unlike thallium 
and technetium-99m sestamibi, the teboroxime has a very 
high extraction fraction at high flow rates such as those 
achieved during adenosine infusion. The washout is biexpo-
nential, with an effective half-life of 12 min in humans. There 
is evidence that differential washout from normal and isch-
emic myocardium may be present, allowing the detection of 
reversible and fixed defects from a single study (13); how-
ever, the accepted clinical protocol requires the use of two 
studies, one during stress and one at rest. The differential 
washout may also suggest that single-photon emission com-
puted tomographic (SPECT) imaging, which requires approxi-
mately 8 min for completion, tends to underestimate the degree 
of ischemia. This obviously requires further studies, especially 
with multihead gamma cameras that can complete the tomo-
graphic imaging within a much shorter period of time. 
The rapid teboroxime clearance requires that imaging be 
performed as soon as possible ( <2 min) after termination of 
exercise. Planar imaging is ideal with this imaging agent 
because each image may be acquired in 40 to 60 s (total 
acquisition time 3 min) (14). Such an imaging sequence might 
permit acquisition of both initial and delayed images within 
10 min (13,14). We have found (6) our modification of the 
SPECT imaging protocol by considerably shortening the 
acquisition time to be very effective for obtaining high 
quality images with teboroxime. The added advantages of 
this technique during adenosine infusion are that the patient 
can be positioned on the imaging table during the infusion 
and imaging can be started as soon as possible after comple-
tion of the infusion, thereby optimizing the interval between 
injection and imaging. 
Pharmacologic stress testing with adenosine. Adenosine is 
a potent vasodilator in most vascular beds, but in the renal 
afferent arterioles and hepatic veins it produces vasocon-
striction (9, 15). Intravenously administered adenosine is 
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Figure 1. Single-photon emission computed tomographic (SPECT) 
adenosine-teboroxime images (upper panels) and rest images (lower 
panels) showing defects. Three short-axis slices at apical, mid and 
basal levels and one vertical long-axis slice at the mid-ventricular 
level are shown. A, Reversible defects. 8, Fixed and reversible 
defects. C, Fixed defect. 
rapidly cleared from the circulation through cellular uptake 
primarily by erythrocytes and vascular endothelial cells. 
Adenosine is thought to exert its pharmacologic effects 
JACC Vol. 19, No. 2 
February 1992:307-12 
through activation of purine receptors (cell surface A1 and 
A2 adenosine receptors). Although the exact mechanism by 
which adenosine receptor activation relaxes vascular 
smooth muscle is not known, there is evidence to support 
both inhibition of the slow inward calcium current, reducing 
calcium uptake, and activation of adenylate cyclase through 
A2 receptors in the smooth muscle cells. Intravenously 
administered adenosine is rapidly metabolized either 
through phosphorylation to adenosine monophosphate by 
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Figure 2. Correlation between adenosine-teboroxime imaging, ex-
ercise thallium imaging and presence or absence of coronary artery 
disease (CAD). A = abnormal; N = normal. 
adenosine kinase or deamination to inosine by adenosine 
deaminase. The half-life is <10 s. In 13.2 patients with 
coronary artery disease, defined as :::::50% diameter stenosis 
in one or more major coronary arteries, and 16 patients with 
normal coronary angiograms, SPECT thallium imaging dur-
ing adenosine infusion at a rate of 140 JLg/kg per min for 
6 min resulted in high quality tomographic images and a high 
degree of sensitivity and specificity (16). The sensitivity was 
87% in the 54 patients with one-vessel disease, 92% in the 37 
patients with two-vessel disease and 98% in the 41 patients 
with three-vessel disease. The specificity was 88% in the 16 
patients with normal coronary angiograms. 
Rationale for using teboroxime with adenosine. The com-
bination of teboroxime imaging during adenosine-induced 
coronary hyperemia appears to offer the maximal advan-
tages of both agents. Thus, studies can be performed with 
the patient on the imaging table and imaging can be started 
immediately after injection; the degree of coronary hyper-
emia is maximal with adenosine; the extraction of teborox-
ime is high at the high flow rates achieved with adenosine; 
both imaging agents have a very short half-life (<10 s for 
adenosine and 12 min for teboroxime); and the imaging 
protocol is short ( < 10 min). We were also encouraged by our 
initial feasibility studies suggesting that teboroxime can be 
imaged with use of SPECT techniques and our high degree of 
accuracy in detecting coronary artery disease using SPECT 
thallium imaging during adenosine infusion (6,16). 
Results of the present study. Our results suggest that 
SPECT imaging with teboroxime during adenosine infusion is 
Figure 3. Correlation between teboroxime and thallium images in a 
segment by segment analysis. The segments were considered nor-
mal, fixed or reversible. 
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feasible, produces high quality images and results in data that 
generally correlate quite well with those obtained with thal-
lium-201 (Fig. 1 to 3). Uptake of teboroxime in the liver is 
considerable because of the hepatic clearance ofthe teborox-
ime and because adenosine, unlike exercise, does not result in 
a redistribution of regional cardiac output. The latter mecha-
nism also explains the considerable thallium uptake in the liver 
during adenosine thallium imaging. In two patients intense 
uptake of teboroxime in the left lobe of the liver resulted in an 
apparent fixed perfusion defect involving the inferior wall. This 
reconstruction artifact, which is caused by extracardiac activ-
ity, is similar to that observed in the spine during bone scanning 
in the presence of intense uptake in the bladder (17). In general, 
the hepatic uptake of teboroxime, like the hepatic uptake of 
thallium during adenosine studies (in contrast to exercise 
studies), does not interfere with SPECT imaging. Neverthe-
less, uptake of teboroxime in the liver is probably greater than 
that of thallium during adenosine studies because teboroxime, 
unlike thallium, is cleared through the liver. Examination of the 
raw data is helpful in ascertaining whether the abnormality is 
due to artifact. Most patients with coronary artery disease had 
abnormal teboroxime and thallium images, with good agree-
ment between the two methods in defining the presence and 
nature of perfusion abnormality as fixed or reversible (Fig. 2, 
3). 
Our study was a feasibility evaluation of the imaging 
technique; it was limited by a small sample size and was not 
designed to address the issues of specificity and sensitivity. 
Discussion of these issues should await further studies in a 
much larger group of patients. On a theoretic basis, the 
combination of teboroxime imaging during adenosine-
induced coronary hyperemia appears to be an attractive 
techniques for detecting of mild or moderate coronary artery 
disease, which requires not only the presence of maximal 
coronary hyperemia in the normal artery, but also a tracer 
that has a high extraction fraction in the presence of high 
flow state. The application of this technique to the study of 
progression and regression of coronary atherosclerosis is 
another area that needs further study. 
Conclusions. Our preliminary results suggest the feasibil-
ity of performing SPECT imaging with teboroxime during 
adenosine infusion with use of a single-headed gamma cam-
era. It is hoped that these results will stimulate further 
research in comparing adenosine with exercise teboroxime 
imaging, as well as imaging with thallium or technetium-99m 
sestamibi during adenosine-, dipyridamole- or dobutamine-
induced coronary hyperemia. 
We thank Susan Kelchner for expert secretarial assistance in preparation of 
the manuscript. 
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